

## DAFTAR PUSTAKA

- Agustini, D. D., Surahman, E., & Abdulah, R. (2015). Kualitas Hidup Pasien Kanker Payudara Dengan Terapi Kombinasi Quality Of Life Patients With Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, And Cyclofosfamide. *Jurnal Farmasi Klinik Indonesia*, 4(3), 175-85.
- American Cancer Society. 2021. *What Is Breast Cancer ?* 1–50.
- American Cancer Society. 2023. What is cancer? *Practice Nursing*, 8(18), 27–29. <https://doi.org/10.12968/pnur.1997.8.18.27>
- American Cancer Society. 2023. Breast Cancer: Treating Breast Cancer. *American Cancer Society*, 1–99. <https://www.cancer.org/cancer/breast-cancer/treatment.html>
- Anoop, T. M., Joseph P, R., Soman, S., Chacko, S., & Mathew, M. 2022. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. *World Journal of Clinical Oncology*, 13(6), 529–539. <https://doi.org/10.5306/wjco.v13.i6.529>
- Ardizzoni A, Cafferata M.A, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Decline in Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment During Chemotherapy Predicts Objective Response and Survival in Patients with Advanced Nonsmall Cell Lung Cancer. *Cancer*. 2006; 107: 2842-9
- Arnold, M., Morgan, E., Rungay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. 2022. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*, 66(August), 15–23. <https://doi.org/10.1016/j.breast.2022.08.010>
- Aziz, M Farid; Andrijono; Abdul Bari Saifuddin; 2010. *Buku Acuan Nasional Onkologi Ginekologi*. Jakarta: PT Bina Pustaka Sarwono Prawirahardjo, 768 halaman
- Baratawidjaja; Karnen Garna; Iris Rengganis; 2018. *Imunologi Dasar*, Jakarta:FKUI, 687 halaman
- Desen, W. 2008. *Buku Ajar Onkologi Klinis* diterjemahkan oleh Willie Japaris, FKUI, Jakarta, 657 halaman
- Efendi, A. A., Hamdani, W., & Labeda, I. (2012). Pengaruh Kemoterapi Terhadap Kadar Ca 15-3 dan Cea dalam Darah Penderita Kanker Payudara Stadium Lanjut. *JST Kesehatan*, 1(3), 272-280
- Global Cancer Observatory, 2020. Population Fact Sheets. Available at:

<https://gco.iarc.fr/today/fact-sheets-populations> [Accessed November 15,2023].

Hasan, D. (2022). Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients. *Journal of Circulating Biomarkers*, 11(9), 57–63. <https://doi.org/10.33393/jcb.2022.2446>

Kabel, A. M. (2017). Tumor markers of breast cancer: New prospectives. *Journal of Oncological Sciences*, 3(1), 5-11.

Kemenkes RI. 2018. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara*. 53(1), 111.

Kemenkes R1, 2021. Deteksi Dini Kanker Payudara dengan SADARI dan SADANIS. Available at: <https://upk.kemkes.go.id/new/deteksi-dini-kanker-payudara-dengan-sadari-dan-sadanis> [Accessed Juni 30,2024].

Kemenkes RI, 2022. Kanker berulang (Reccurence): Deteksi Dini dan Pencegahan. Available at: [https://yankes.kemkes.go.id/view\\_artikel/738/kanker-berulang-recurrence-deteksi-dini-dan-pencegahan](https://yankes.kemkes.go.id/view_artikel/738/kanker-berulang-recurrence-deteksi-dini-dan-pencegahan) [Accessed November 22,2023].

Kresno S.(2003). Ilmu Dasar Onkologi. Jakarta: Patologi Klinik FKUI; 2003

Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15–3 and CEA serum levels have independently poor prognostic significance in breast cancer. *Ann Oncol* 2013; 24:1225–1231. doi: 10.1093/annonc/mds604 PMID: 23230137

Lumachi, F., Brandes, A. A., Ermani, M., Bruno, G., & Boccagni, P. (2000). Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. *Anticancer research*, 20(6C), 4751-4755.

Lusiani Tjandra. 2019. *Proto oncogen.Jurnal ilmiah kedokteran*

Matdoan, A. T. S., Rijal, S., Musa, I. M., Irsandy, F., & Kamaluddin, I. D. K. (2024). Karakteristik Penderita Kanker Payudara Pre dan Post Kemoterapi di RS Ibnu Sina Makassar Tahun 2022. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, 4(2), 119-126.

Molina, R., Auge, J. M., Farrus, B., Zanon, G., Pahisa, J., Munoz, M., ... & Velasco, M. (2010). Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. *Clinical chemistry*, 56(7), 1148-1157.

National Cancer Institute. 2020. Recurrent Cancer: When Cancer Comes Back. *Cancer.Gov*, 5(2), 2–3. <https://www.cancer.gov/types/recurrent-cancer>

- Nicholson, B. D., Shinkins, B., Pathiraja, I., Roberts, N. W., James, T. J., Mallett, S., Perera, R., Primrose, J. N., & Mant, D. 2014. Blood CEA levels for detecting recurrent colorectal cancer. *Cochrane Database of Systematic Reviews*, 2014(6). <https://doi.org/10.1002/14651858.CD011134>
- Park, B., Oh, J., Kim, J., Park, S. H., Kim, K., Kim, J. H., & Lee, K. S. (2008). *Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. April 1999*, 675–681. <https://doi.org/10.1093/annonc/mdm538>
- Rasjidi, I. 2009. *Deteksi dini pencegahan kanker pada wanita*, Jakarta:Sagung Seto, 279 halaman.
- Santosa, B. 2020. *Teknik Elisa*, Semarang: Unimus-press, 35 halaman
- Sofa, T., Wardiyah, A., & Rilyani, R. (2024). Faktor Risiko Kanker Payudara pada Wanita. *Jurnal Penelitian Perawat Profesional*, 6(2), 493-502.
- Suyatno;Emir T Pasaribu,2014. *Bedah Onkologi Diagnosis dan Terapi*,Jakarta:Sagung Seto, 254 halaman.
- Vincent RG, Chu TM, Fergen TB, Ostrander M. 1975.Carcinoembryonic Antigen in 228 Patients with Carcinoma of the Lung. *Cancer*. 36:2069- 76.
- World Health Organization, 2023. Breast Cancer. Available at: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer> [Accesed November 15,2023]
- Zhao, S., Mei, Y., Wang, J., Zhang, K., & Ma, R. 2016. Different levels of CEA, CA153 and CA125 in milk and benign and malignant nipple discharge. *PLoS ONE*, 11(6), 1–9. <https://doi.org/10.1371/journal.pone.0157639>